Cristina Zanchi

Science And Technology Park Kilometro Rosso
Bergamo, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Efficacy of GalNAc C3 siRNAs in factor H-deficient mice with C3 glomerulopathy.

Efficacy of GalNAc C3 siRNAs in factor H-deficient mice with C3 glomerulopathy.

Journal: Molecular immunology

Published: November 03, 2023

Liver factor B silencing to cure C3 glomerulopathy: Evidence from a mouse model of complement dysregulation.

Liver factor B silencing to cure C3 glomerulopathy: Evidence from a mouse model of complement dysregulation.

Journal: Molecular immunology

Published: April 19, 2023

Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A/caveolin-1/PV-1 signaling pathway.

Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A/caveolin-1/PV-1 signaling pathway.

Journal: The Journal of pathology

Published: August 04, 2021

Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy.

Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: July 26, 2021

Post-translational modifications by SIRT3 de-2-hydroxyisobutyrylase activity regulate glycolysis and enable nephrogenesis.

Post-translational modifications by SIRT3 de-2-hydroxyisobutyrylase activity regulate glycolysis and enable nephrogenesis.

Journal: Scientific reports

Published: June 25, 2021

CER-001 ameliorates lipid profile and kidney disease in a mouse model of familial LCAT deficiency.

CER-001 ameliorates lipid profile and kidney disease in a mouse model of familial LCAT deficiency.

Journal: Metabolism: clinical and experimental

Published: October 15, 2020

Manipulating Sirtuin 3 pathway ameliorates renal damage in experimental diabetes.

Manipulating Sirtuin 3 pathway ameliorates renal damage in experimental diabetes.

Journal: Scientific reports

Published: January 10, 2020

ADAMTS13 Deficiency Shortens the Life Span of Mice With Experimental Diabetes.

ADAMTS13 Deficiency Shortens the Life Span of Mice With Experimental Diabetes.

Journal: Diabetes

Published: December 13, 2017

SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.

SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.

Journal: JCI insight

Published: November 16, 2017

MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy.

MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy.

Journal: Diabetologia

Published: January 20, 2017

Key pathways in renal disease progression of experimental diabetes.

Key pathways in renal disease progression of experimental diabetes.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: July 26, 2015

Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease.

Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease.

Journal: Nephron

Published: October 13, 2014

Showing 1-12 of 15

Last Updated: 09/26/2026